The evidence for Cannabidiol is building

By Danélia Botes

March 27, 2023

Cannabidiol has been licensed as an add-on treatment for seizures caused by tuberous sclerosis complex for patients aged 2 years and over. Clinical trial evidence shows that it reduces seizure frequency and increases seizure-free days compared to ...

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2024 Syenza™. All rights reserved.